Table 2.
The difference in clinicopathological characteristics between patients (n = 141) with pseudomyxoma peritonei stratified according to Ki67 and p53 immunostaining levels.
| p53, n (%) |
Ki67 LI, n (%) |
|||||
|---|---|---|---|---|---|---|
| Characteristic | Normaln = 94 | Aberrantn = 47 | Statistical analysesa | <50%n = 95 | ≥50%n = 46 | Statistical analysesa |
| Sex | NS | NS | ||||
| Male | 48 (34.0) | 21 (14.9) | 48 (34.0) | 21 (14.9) | ||
| Female | 46 (32.6) | 26 (18.4) | 47 (33.3) | 25 (17.7) | ||
| Age, years | NS | NS | ||||
| <60 | 57 (40.4) | 34 (24.1) | 62 (44.0) | 29 (20.6) | ||
| ≥60 | 37 (26.2) | 13 (9.2) | 33 (23.4) | 17 (12.1) | ||
| Histological grade | P < 0.001 | P < 0.001 | ||||
| LGMC | 81 (57.4) | 12 (8.5) | 77 (54.6) | 16 (11.3) | ||
| HGMC | 12 (8.5) | 31 (22.0) | 18 (12.8) | 25 (17.7) | ||
| HGMC-S | 1 (0.7) | 4 (2.8) | 0 (0.0) | 5 (3.5) | ||
| CEA | NS | NS | ||||
| Positive | 90 (63.8) | 45 (31.9) | 90 (63.8) | 45 (31.9) | ||
| Negative | 4 (2.8) | 2 (1.4) | 5 (3.5) | 1 (0.7) | ||
| Ki67 LI | P = 0.001 | |||||
| <50% | 73 (51.8) | 22 (15.6) | – | – | ||
| ≥50% | 21 (14.9) | 25 (17.7) | – | – | ||
| p53 | P < 0.001 | |||||
| Normal | – | – | 73 (51.8) | 21 (14.9) | ||
| Aberrant | – | – | 22 (15.6) | 25 (17.7) | ||
| Lymph node involvement | P = 0.004 | NS | ||||
| Absent | 92 (65.2) | 39 (27.7) | 91 (64.5) | 40 (28.4) | ||
| Present | 2 (1.4) | 8 (5.7) | 4 (2.8) | 6 (4.3) | ||
| Angiolymphatic invasion | P = 0.001 | NS | ||||
| Absent | 92 (65.2) | 38 (27.0) | 91 (64.5) | 39 (27.7) | ||
| Present | 2 (1.4) | 9 (6.4) | 4 (2.8) | 7 (5.0) | ||
| Perineural invasion | NS | P = 0.018 | ||||
| Absent | 93 (66.0) | 44 (31.2) | 95 (67.4) | 42 (29.8) | ||
| Present | 1 (0.7) | 3 (2.1) | 0 (0.0) | 4 (2.8) | ||
Data presented as n of entire study cohort of 141 (%).
aCategorical data were compared using χ2-test or Fisher's exact test; NS, no significant association (P ≥ 0.05).
LGMC, low-grade mucinous carcinoma; HGMC, high-grade mucinous carcinoma; HGMC-S, high-grade with signet ring cells; CEA, carcinoembryonic antigen; LI, labelling index.